Background Transcatheter arterial chemoembolization (TACE) 
Introduction

Transcatheter arterial chemoembolization (TACE) is increasingly being used to treat inoperable primary and secondary liver malignancies (1-3). The procedure is generally well tolerated, with major complications in only 4-7% of procedures and a 30-day mortality of approximately 1%
. However, the procedure has been associated with several complications such as acute hepatic failure (2.6% of 
F i g u r e 1 . S c h e me o f s t u d y p r o t o c o l .
lighter and less of a burden is imposed on patients. However, it has not been determined whether intravenous or oral administration provides better prophylaxis against infectious complications after TACE. Prophylactic administration of cephazolin (CEZ) and levofloxacin (LVFX) is commonly used for patients undergoing invasive procedures for liver
and biliary diseases (9) (10) (11) (12) . Therefore, we compared the efficacy of oral LVFX and intravenous CEZ for prophylaxis against infectious complications in patients undergoing transcatheter therapy for hepatocellular carcinoma using a prospective study design. (4, 5, 14 
Patients and Methods
Patients
Patients were eligible for enrollment if they had hepatocellular carcinoma (HCC) and were scheduled to undergo TACE or transcatheter arterial infusion chemotherapy (TAI
Statistical analysis
Post-transcatheter treatment infections are reported to occur in 3.7% , 4-8% , 3.3% , and 11% of patients (5, 8, 16, 17 (Fig. 1 ). There were no significant differences between the two groups in terms of baseline characteristics before and after exclusion of these 15 cases (Table 1-a, b) .
Results
Baseline characteristics of the patients
Adverse and infectious events
The numbers of adverse and infectious events are described in T a b l e 1 -a . B a s e l i n e Ch a r a c t e r i s t i c s o T a b l e 3 . P r e f e r e n c e o f P a t i e n t (13) . In fact, transcatheter treatment of HCC is reportedly accompanied by post-procedure infectious complications in 3-11% of cases (5, 8, 16, 17) .
T a b l e 1 -b . B a s e l i n e Ch a r a c t e r i s t i c s o f An a l y z e d P a t i e n t s
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Changes in inflammatory markers
Peripheral leukocyte counts and serum CRP levels peaked on the 4th day after transcatheter treatment. There was no significant inter-group difference in these parameters at any of the assessed time points (Figs. 2, and 3). We also classified the enrolled patients into TACE-treated (n=121) and TAI-treated (n=8) subgroups, and assessed their differences in regard to inflammatory markers based on CEZ or LVFX
F i g u r e 2 . Ch a n g e s i n p e r i p h e r a l l e u k o c y t e n u mb e r . T h e r e wa s n o s i g n i f i c a n t d i f f e r e n c e i n t h e l e u k o c y t e c o u n t s b e t we e n t h e CE Z ( n = 6 4 ) a n d L VF X ( n = 6 5 ) g r o u p s . S t a t i s t i c a l a n a l y s i s wa s d o n e b y r e p e a t e d me a s u r e s ANOVA.
F i g u r e 3 . Ch a n g e s i n s e r u m CRP l e v e l s . T h e r e wa s n o s i g n i f i c a n t d i f f e r e n c e i n s e r u m CRP l e v e l b e t we e n t h e CE Z ( n = 6 4 ) a n d L VF X ( n = 6 5 ) g r o u p s . S t a t i s t i c a l a n a l y s i s wa s d o n e b y r e p e a t e d me a s u r e s ANOVA.
T a b l e 2 . Nu mb e r s o f E v e n t s
Since bacterial infection can be introduced not only via the percutaneous route but also via the trans-biliary route, various kinds of gram-positive and -negative bacteria including
Streptococcus species, Klebsiella species, and Escherichia coli have been reported to be pathogenic organisms (5, 8, 9, 16 
